VENTOLIN
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Jan 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
VENTOLIN by GSK is 2 -adrenergic receptors compared with isoproterenol. Approved for exercise-induced bronchospasm in adult, older. First approved in 1987.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENTOLIN is a branded inhalation solution approved in 1987 by GSK for respiratory indications requiring bronchodilation. The product is a small-molecule bronchodilator delivered via inhalation route. It represents a foundational therapy in respiratory medicine with decades of clinical use.
LOE Approaching
Approaching loss of exclusivity creates urgency for lifecycle management and genericization-defense strategies; expect consolidation of commercial teams around core markets.
Mechanism of Action
2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50%…
Indications (2)
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.